NCT04911738 VIrtual Reality Glasses Use to Improve Lateropulsion and the Post-stroke Postural Vertical
| NCT ID | NCT04911738 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Grenoble |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2021-06-15 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2021-06-15 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
VIRGIL is a monocentric interventional study aiming to investigate the effect of immersion in a virtual tilted room on modulation of the verticality representation (postural vertical \[PV\] and visual vertical \[VV\]), which in turn might affect body orientation (head and trunk). To this end, the investigators will conduct a within-person randomized trial including post-stroke patients and healthy participants.
Eligibility Criteria
Inclusion Criteria: * 20 stroke participants * Hospitalized in neurorehabilitation * Hemisphere stroke (Right or left) * Stroke delay \< 6 months * Presence of lateropulsion assessed by the Scale for Contraversive Pushing (SCP) \> 0.5 * 20 healthy participants * No history of stroke or others neurological pathologies * No balance disorders * No history of vestibular or dizzissness disorders Exclusion Criteria: * All * History of psychiatric disorders * Nyctophobia * Advanced heart failure * Severe trunk deformation with C7 lateral \> 30 mm due to a independant cause beyond the stroke (i.e., scoliosis) or history of postural disorder * 20 Stroke participants * Medical instability making the assessment impossible * Comprehension deficits with Boston Diagnostic Aphasia Examination gravity score ≥3 * History of vestibular or dizzissness disorders * No previous neurological history interfering with balance * Inability to understand and execute simple orders * Severe untreated depression (Aphasic Depression Rating Scale (ADRS) score \>15)
Contact & Investigator
Dominic Pérennou
PRINCIPAL INVESTIGATOR
University Hospital, Grenoble
Frequently Asked Questions
Who can join the NCT04911738 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04911738 currently recruiting?
Yes, NCT04911738 is actively recruiting participants. Contact the research team at DPerennou@chu-grenoble.fr for enrollment information.
Where is the NCT04911738 trial being conducted?
This trial is being conducted at Grenoble, France.
Who is sponsoring the NCT04911738 clinical trial?
NCT04911738 is sponsored by University Hospital, Grenoble. The principal investigator is Dominic Pérennou at University Hospital, Grenoble. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.